Abstract
A satellite symposium titled ‘Transforming MS Care: Early Intervention and Sustained Safety’ held at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) discussed current challenges and future advances in the management of multiple sclerosis (MS). The symposium discussed the importance of early intervention with disease-modifying therapy (DMT) in people with MS. The session explored the effects of DMT switching in patients with MS, and discussed data on the persistence, patient satisfaction, and long-term safety associated with DMTs. The DAYBREAK OLE trial investigating once-daily ozanimod showed that early treatment with high-efficacy DMT is essential to improve disability outcomes, preserve cognition, and delay MS disease progression.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call